<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03885947</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 14-0451</org_study_id>
    <nct_id>NCT03885947</nct_id>
  </id_info>
  <brief_title>VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies</brief_title>
  <official_title>Phase I Study of Valproic Acid Expanded Cord Blood Stem Cells as an Allogeneic Donor Source for Adults With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alla Keyzner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this Phase I study, the study team will evaluate the safety of Valproic Acid (VPA)
      expanded cord blood stem cells defined by the lack of serious infusion reactions or graft
      failure in patients with hematological malignancies undergoing umbilical cord blood
      transplantation. Moreover, the study team will also evaluate time to neutrophil and platelet
      engraftment as well as transplant related outcomes such as graft versus host disease (GVHD),
      treatment related mortality (TRM), and overall survival (OS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I trial for safety of VPA expanded cord blood stem cells in patients with
      hematological malignancies undergoing allogeneic stem cell transplantation. The primary
      endpoint of the study is safety as defined by the incidence of infusion reactions and graft
      failure, lack of neutrophil engraftment by day +42. The trial will consist of two cohorts.
      First cohort of 5-7 patients, will undergo double umbilical cord blood (UCB) transplantation.
      One UCB unit will undergo CD34 selection followed VPA based expansion. CD34 negative portion
      of that unit will be cryopreserved to be infused later following infusion of the expanded
      portion. Infusion of the second unmanipulated UCB will follow it. Preparative regimen is
      Fludarabine 150 mg/m2/Cytoxan 50 mg/m2/Thiotepa 10 mg/m2/TBI 400cGy.

      Following successful engraftment in the first cohort, second cohort (10 patients) will only
      receive single manipulated unit.

      Otherwise, patients will receive standard allogeneic stem cell transplantation care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">January 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open label single arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Infusion Reaction</measure>
    <time_frame>42 days</time_frame>
    <description>Safety as measured by the incidence of infusion related reactions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Graft Failure</measure>
    <time_frame>42 days</time_frame>
    <description>Safety as measured by the incidence of graft failures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant related outcomes: time to neutrophil engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelets engraftment</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant related outcomes: time to platelets engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of transplant-related mortality (TRM)</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant related outcomes: transplant-related mortality (TRM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of disease free survivals</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant related outcomes: Number of disease free survivals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of overall survivals</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant related outcomes: Number of overall survivals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants at risk of GVHD</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant Related Outcomes: risk of GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infectious complications</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant Related Outcomes: incidence of infectious complications - which is any documented bacterial, viral, or fungal infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to myeloid engraftment</measure>
    <time_frame>42 days</time_frame>
    <description>Assess the kinetics of engraftment and immune reconstitution by assessing time to myeloid engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to lymphoid engraftment</measure>
    <time_frame>42 days</time_frame>
    <description>Assess the kinetics of engraftment and immune reconstitution by assessing time to lymphoid engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in T cell count</measure>
    <time_frame>Baseline and 42 days</time_frame>
    <description>Assess the kinetics of engraftment and immune reconstitution by assessing the T cell count at 42 days as compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Hematological Malignancy</condition>
  <condition>Acute Leukemia in Remission</condition>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood for patients with hematological malignancies undergoing allogeneic stem cell transplantation.
VPA expanded cord blood stem cells in patients with hematological malignancies undergoing allogeneic stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cord blood stem cells</intervention_name>
    <description>CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood .</description>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>Valproic Acid (VPA) expanded cord blood stem cells</description>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
    <other_name>VPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 150 mg/m2</description>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytoxan</intervention_name>
    <description>Cytoxan 50 mg/m2</description>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Thiotepa 10 mg/m2</description>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TBI</intervention_name>
    <description>TBI 400cGy</description>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Disease criteria:

        Patients with the following hematological malignancies:

          -  Acute Myeloid Leukemia (AML) in complete remission (CR)

          -  Acute Lymphoblastic Leukemia (ALL) in complete remission (CR)

          -  Myelodysplastic Syndrome (MDS) requiring intensive chemotherapy

          -  Non-Hodgkin lymphoma in complete or partial remission

          -  Hodgkin lymphoma in complete or partial remission

        Age Criteria:

        - 18 years up to 65 years.

        Organ Function and Performance Status Criteria:

        - Performance status score: Karnofsky Score ≥60

        Adequate major organ function defined as:

          -  Left ventricular ejection fraction ≥40%

          -  Pulmonary function test demonstrating DLCO ≥50% predicted and corrected for hemoglobin

          -  Serum creatinine ≤ 2 mg/dL

          -  Transaminases ≤ 3x ULN

          -  Bilirubin ≤3x ULN except for in case of Gilbert's syndrome or ongoing hemolysis

          -  Ability to understand and the willingness to sign a written informed consent document

        Donor availability:

        -Lack of suitable HLA matched related or unrelated donor available within 30 days or less
        if BMT is urgent in the opinion of the transplant physician.

        Exclusion Criteria:

          -  Progressive, persistent disease or active malignancy

          -  Greater than 10% blasts on bone marrow biopsy in patients with MDS

          -  Chemotherapy naïve

          -  History of myelofibrosis

          -  Presence of Bone Marrow Fibrosis grade 2/3

          -  Presence of donor specific anti-HLA antibodies against available UCB units at A, B, C
             or DR loci, with a mean fluorescence intensity (MFI)&gt;1000

          -  History of prior allogeneic stem cell transplantation

          -  Uncontrolled viral, bacterial or fungal infection

          -  History of HIV infection

          -  Presence of active CNS disease at the time of transplantation

          -  Pregnant or breastfeeding female

          -  Inability or unwillingness to use effective birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alla Keyzner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Artur Shchukin, MS</last_name>
    <phone>212-241-6021</phone>
    <email>artur.shchukin@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alla Keyzner, MD</last_name>
    <phone>212-241-6021</phone>
    <email>alla.keyzner@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alla Keyzner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Alla Keyzner</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Hematological Malignancies</keyword>
  <keyword>Expanded Umbilical Cord</keyword>
  <keyword>Allogeneic Stem Cell Transplant</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

